Innovative nanoplatform for bitherapy of glioblastoma

Glioblastoma (GBM) is an aggressive brain tumor with a very poor prognosis. Current treatments are not curative and consist of tumor resection when feasible, followed by fractionated radiotherapy (RT) and chemotherapy with temozolomide. The primary challenges in treating GBM are the inherent radio- and chemoresistance of GBM cells.

We are developing a novel treatment based on image-guided bitherapy for GBM, utilizing polymeric and biodegradable nanoparticles (NPs) specifically designed for localized chemoradiotherapy (CRT).

Radiosensitizing gold nanoparticles (GNPs), coated with imaging agents such as gadolinium and indium-111, along with the anticancer drug paclitaxel, are co-loaded into the NPs.

Our proof-of-concept study demonstrated that the combination of GNPs and paclitaxel enhanced the efficacy of radiotherapy in both an orthotopic glioblastoma and a xenograft prostate cancer mouse model.

In order to complete the preclinical phase and initiate clinical trials, Orinova, a startup dedicated to pioneering approaches for treating localized tumors, is set to be launched next month by a team of five professionals:

• Arnaud Beduneau, a distinguished professor specializing in galenic pharmacy, with expertise in nanovectorization and preclinical evaluation;

• Stéphane Roux, a seasoned professor of chemistry, focusing on nanoparticles for healthcare applications;

• Gautier Laurent, a research engineer specializing in healthcare nanoparticles and nanovectorization;

• Asli Goctu, a PhD student specializing in nanoparticles and cell culture with entrepreneurship training for business start-ups.

• Jean-Marc Zeil, a seasoned CEO with a diverse portfolio spanning the health and food industries.